Fermented soy milk prepared using kefir grains prevents and ameliorates obesity, type 2 diabetes, hyperlipidemia and Liver-Kidney toxicities in HFFD-rats.

• The effect of the fermentation of Soymilk by kefir on α-amylase and lipase activity during fermentation. • Study of the effect of soy milk administration on metabolic parameters in obese rats. • A histological study of the effect of obesity and fermented soy milk on liver and kidney tissues. In vitro , this study showed that unfermented soy milk (USM) and kefir fermented soy milk (FSM) inhibited pancreas lipase with (IC 50 = 52.17 and 39.37 μg/mL) and α-amylase activities with (IC 50 = 72.60 and 52.71 μg/mL respectively). The most powerful lipase and α -amylase inhibitory activity was observed around 16 h of fermentation. In HFFD rats, the supplement of FSM increased locomotor performance; and decreased intestinal and pancreas lipase activity by 34 and 35% as compared to untreated HDF-rats. This leads to decrease in TC and LDL-c by 24 and 66%; and increase in HDL-c rates of HFFD-rats by 32%, which helped to decrease in body weight by 20%. Moreover administration of FSM to HFFD-rats inhibited intestinal and pancreas α-amylase activity by 26 and 31% as compared to untreated HFFD-rats, and consequently decrease of blood glucose by 36%. In addition, FSM efficiently was protected from hepatic and kidney tissues toxicities. [ABSTRACT FROM AUTHOR]